Terlipressin

Cat. No.: HY-12554
CAS No.: 14636-12-5
Molecular Formula: C₅₂H₇₄N₁₆O₁₅S₂
Molecular Weight: 1227.37
Sequence: Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH₂ (Disulfide bridge: Cys4-Cys9)
Sequence Shortening: GGGCYFQNCPKG-NH₂ (Disulfide bridge: Cys4-Cys9)
Target: Vasopressin Receptor
Pathway: GPCR/G Protein
Storage: Powder
-80°C 2 years
-20°C 1 year
In solvent
-80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro DMSO: ≥ 12.3 mg/mL (10.02 mM)
* “≥” means soluble, but saturation unknown.

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>0.8148 mL</td>
<td>4.0738 mL</td>
<td>8.1475 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.1630 mL</td>
<td>0.8148 mL</td>
<td>1.6295 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.0815 mL</td>
<td>0.4074 mL</td>
<td>0.8148 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description Terlipressin is a potent vasoconstrictor that acts via V1 receptors on arteriolar smooth muscle cells. Terlipressin can result in splanchnic vasoconstriction augmenting systemic arterial blood pressure with beneficial circulatory and renal effects that would be expected to also ameliorate the key pathophysiological changes responsible for the development of refractory ascites.

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898                Fax: 609-228-5909                E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA